In this study, the combination of rosiglitazone and liraglutide induced lipogenic trans-differentiation, resulting in increased lipid droplet production in cancer cells, as well as up-regulation of the expression of the mature adipose marker FABP4, the adipocyte-specific markers CEBPα, and UCP1 in RT-qPCR. Here, CEBPA is linked to cancer.